Caris Life Sciences, Inc. Common Stock - Asset Resilience Ratio

Latest as of March 2026: 0.20%

Caris Life Sciences, Inc. Common Stock (CAI) has an Asset Resilience Ratio of 0.20% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.

Liquid Assets

$2.31 Million
Cash + Short-term Investments

Total Assets

$1.16 Billion
All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio Trend (2009–2025)

This chart shows how Caris Life Sciences, Inc. Common Stock's Asset Resilience Ratio has changed over time. See Caris Life Sciences, Inc. Common Stock leverage flexibility ratio to measure the company's free cash flow as a share of total liabilities.

Liquid Assets Composition Over Time

This chart breaks down Caris Life Sciences, Inc. Common Stock's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Caris Life Sciences, Inc. Common Stock worth.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents $0.00 0%
Short-term Investments $2.31 Million 0.2%
Total Liquid Assets $2.31 Million 0.20%

Asset Resilience Insights

  • Limited Liquidity: Caris Life Sciences, Inc. Common Stock maintains only 0.20% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Caris Life Sciences, Inc. Common Stock Industry Peers by Asset Resilience Ratio

Compare Caris Life Sciences, Inc. Common Stock's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
CSL Ltd
AU:CSL
Biotechnology 0.41%
Shanghai Allist Pharmaceuticals Co. Ltd. A
SHG:688578
Biotechnology 21.11%
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252
Biotechnology 2.03%
Abivax SA
PA:ABVX
Biotechnology 2.34%
Chongqing Zhifei Bio Products
SHE:300122
Biotechnology -0.08%
Jinyu Bio-Technology Co Ltd
SHG:600201
Biotechnology 1.20%
Sinopep-Allsino Biopharmaceutical Co. Ltd. A
SHG:688076
Biotechnology 2.30%
Wuhan Keqian Biology Co Ltd
SHG:688526
Biotechnology 19.42%

Annual Asset Resilience Ratio for Caris Life Sciences, Inc. Common Stock (2009–2025)

The table below shows the annual Asset Resilience Ratio data for Caris Life Sciences, Inc. Common Stock.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 0.20% $2.29 Million $1.13 Billion -0.44pp
2024-12-31 0.64% $2.20 Million $343.73 Million -15.15pp
2023-12-31 15.79% $65.18 Million $412.90 Million -26.37pp
2022-12-31 42.16% $302.43 Million $717.42 Million +39.13pp
2020-12-31 3.02% $78.99 Million $2.61 Billion +0.50pp
2018-12-31 2.52% $75.97 Million $3.01 Billion +1.28pp
2017-12-31 1.24% $30.06 Million $2.43 Billion +0.27pp
2016-12-31 0.97% $19.96 Million $2.06 Billion -0.09pp
2015-12-31 1.07% $21.16 Million $1.99 Billion +0.05pp
2014-12-31 1.01% $18.15 Million $1.80 Billion +0.23pp
2013-12-31 0.78% $13.00 Million $1.68 Billion +0.01pp
2012-12-31 0.77% $10.62 Million $1.39 Billion +0.12pp
2011-12-31 0.65% $6.16 Million $953.37 Million +0.00pp
2010-12-31 0.64% $3.95 Million $613.45 Million -1.17pp
2009-12-31 1.81% $6.78 Million $374.08 Million --
pp = percentage points

About Caris Life Sciences, Inc. Common Stock

NASDAQ:CAI USA Biotechnology
Market Cap
$4.39 Billion
Market Cap Rank
#3835 Global
#1338 in USA
Share Price
$15.52
Change (1 day)
-0.83%
52-Week Range
$14.55 - $39.30
All Time High
$39.30
About

Caris Life Sciences, Inc., an artificial intelligence TechBio company, provides molecular profiling services in the United States and internationally. It develops and commercializes solutions to transform healthcare using molecular information, and artificial intelligence/machine learning algorithms. The company's molecular intelligence product portfolio includes MI Profile Platform, a whole exom… Read more